Nguyen Duc Nam, Spapen Herbert, Su Fuhong, Schiettecatte Johan, Shi Lin, Hachimi-Idrissi Said, Huyghens Luc
Critical Care Department, Vrije Universiteit Brussel, Brussels, Belgium.
Crit Care Med. 2006 Jul;34(7):1967-74. doi: 10.1097/01.CCM.0000217218.51381.49.
We investigated whether serum levels of neuron-specific enolase (NSE) and S-100beta protein could be used to evaluate cerebral injury and to predict outcome in severe sepsis and severe septic shock.
Prospective study.
University hospital.
In 170 consecutively enrolled patients with severe sepsis and septic shock, serum S-100beta and NSE were measured daily during four consecutive days after intensive care unit admission. Admission Glasgow Coma Scale before sedation and daily Sequential Organ Failure Assessment scores were recorded in all patients. Acute encephalopathy was defined as either a state of agitation, confusion, irritability, and convulsions (type A) or characterized by somnolence, stupor, and coma (type B) and persistently observed during 72 hrs after withdrawing sedation. When clinically indicated, contrast computed tomography or magnetic resonance imaging were performed to evaluate brain injury.
S-100beta and NSE increased in, respectively, 72 (42%) and 90 (53%) patients. High biomarker levels were associated with the maximum Sequential Organ Failure Assessment scores (p = .001), and the highest values were found in patients who died early, within 4 days of inclusion (p = .005). Low consciousness encephalopathy type B was more frequently observed in patients with elevated S-100beta (p = .004). S-100beta levels of >or=4 microg/L were associated with severe brain ischemia or hemorrhage, and values of <2 microg/L were found in patients with diffuse cerebral embolic infarction lesions. High S-100beta levels were associated with higher intensive care unit mortality (p = .04) and represented the strongest independent predictor of intensive care unit survival, whereas NSE and the Glasgow Coma Scale failed to predict fatal outcome.
S-100beta and NSE are frequently increased and associated with brain injury in patients with severe sepsis and septic shock. S-100beta levels more closely reflected severe encephalopathy and type of brain lesions than NSE and the Glasgow Coma Scale.
我们研究了血清神经元特异性烯醇化酶(NSE)和S-100β蛋白水平是否可用于评估严重脓毒症和严重脓毒性休克患者的脑损伤并预测其预后。
前瞻性研究。
大学医院。
在170例连续入选的严重脓毒症和脓毒性休克患者中,入住重症监护病房后的连续4天每天测量血清S-100β和NSE。记录所有患者镇静前的入院格拉斯哥昏迷量表评分和每日序贯器官衰竭评估评分。急性脑病定义为躁动、意识模糊、易怒和抽搐状态(A型)或表现为嗜睡、昏迷和昏睡状态(B型),且在停用镇静剂后72小时内持续存在。临床指征明确时,进行对比计算机断层扫描或磁共振成像以评估脑损伤。
分别有72例(42%)和90例(53%)患者的S-100β和NSE升高。生物标志物高水平与最高序贯器官衰竭评估评分相关(p = 0.001),且在入选后4天内早期死亡的患者中发现最高值(p = 0.005)。S-100β升高的患者更常观察到低意识B型脑病(p = 0.004)。S-100β水平≥4μg/L与严重脑缺血或出血相关,而<2μg/L的值见于弥漫性脑栓塞梗死病变患者。S-100β高水平与重症监护病房死亡率较高相关(p = 0.04),是重症监护病房生存的最强独立预测指标,而NSE和格拉斯哥昏迷量表未能预测致命结局。
严重脓毒症和脓毒性休克患者中,S-100β和NSE常升高且与脑损伤相关。与NSE和格拉斯哥昏迷量表相比,S-100β水平更能密切反映严重脑病和脑损伤类型。